This article first appeared on GuruFocus. Novo Nordisk (NVO, Financials), has agreed to pay up to 1.165 billion ($1.3 billion) for access to drug-delivery technology that could help the company develop obesity and diabetes treatments requiring fewer injections. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart The Danish drugmaker signed a global licensing and collaboration agreement with Sweden's Nanexa covering its PharmaShell technology for certain therapeutic peptide drugs. The deal could cover as many as five development programs targeting obesity, type 2 diabetes and other cardiometabolic diseases.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.